Expression of regulatory proteins and proliferative activity in relation to phenotypic characteristics of upper urothelial carcinoma

Dolićanin, Zana; Veličković, Ljubinka Janković; Djordjević, Biljana; Visnjic, Milan; Pešić, Ivan; Ristic, Ana; Marjanović, Vesna

doi:10.2298/vsp1107567d

Cited by 6 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Molecular tumor markers hold considerable promise for accurately predicting the recurrence and progression of NMIBC patients treated with BCG intravesical therapy. Deregulation of the cell-cycle machinery is common in bladder cancer, involving alterations in various proteins such as cyclin D1, Rb, p16, p21, p27, and p53 [ 5 , 6 ]. The value of pretreatment p53 overexpression on the prognosis of NMIBC patients treated with BCG has been widely studied and discussed.…”

Section: Introductionmentioning

confidence: 99%

p53 Status Correlates with the Risk of Recurrence in Non-Muscle Invasive Bladder Cancers Treated with Bacillus Calmette–Guérin: A Meta-Analysis

2015

View full text Add to dashboard Cite

ObjectivePublished studies have yielded inconsistent results on the relationship between p53 status and the prognosis of non-muscle invasive bladder cancer (NMIBC) treated with Bacillus Calmette–Guérin (BCG) intravesical therapy. Therefore, we performed a meta-analysis to evaluate the prognostic value of p53 in NMIBC treated with BCG.MethodsWe systematically searched for relevant literature in PubMed, EMBASE, CNKI, and Chinese Wanfang databases. Hazard ratios (HRs) with 95% confidence intervals (CIs) were combined as the effect size (ES) across studies for recurrence-free survival (RFS) and progression-free survival (PFS).ResultsA total of 11 studies, consisting of 1,049 participants, met the criteria. Overall, there was no clear relationship between p53 status and RFS or PFS for NMIBC patients treated with BCG (HR: 1.40, 95% CI: 0.91-2.16; HR: 1.37, 95% CI: 0.90-2.09, respectively). Obvious heterogeneity was observed across the studies (I2 = 69.5%, P = 0.001; I2 = 44.7%, P = 0.081, respectively). In stratified analysis by region, p53 overexpression was a predictor of poor RFS in Asian populations (HR: 1.57, 95% CI: 1.08-2.27). In addition, after excluding the studies that possibly contributed to the heterogeneity by the Galbraith plot, the overall association for RFS became statistically significant (HR: 1.38 95% CI: 1.08-1.77) without evidence of heterogeneity (I2 = 0.0%, P = 0.499).ConclusionThis meta-analysis suggests that p53 overexpression in NMIBC patients treated with BCG may be associated with RFS, especially in Asian populations. Because of the heterogeneity and other limitations, further studies with rigid criteria and large populations are still warranted to confirm our findings.

show abstract

Section: Introductionmentioning

confidence: 99%

p53 Status Correlates with the Risk of Recurrence in Non-Muscle Invasive Bladder Cancers Treated with Bacillus Calmette–Guérin: A Meta-Analysis

2015

View full text Add to dashboard Cite

show abstract

“…In normal cells, p53 can induce cell cycle arrest at the G0/G1 phase and cell apoptosis; and when it is mutated, as in the case of several types of tumor, p53 loses its regulatory role and promotes tumor progression (32). Deregulation of cell-cycle machinery involving alterations in p53 is common in bladder cancer (33), breast cancer (34), lung cancer (35) and CRC (36). Significant differences in p53 staining between CRC tissues and normal control tissues have been reported in previous studies (17,18).…”

Section: Discussionmentioning

confidence: 99%

Combined detection of the expression of Nm23-H1 and p53 is correlated with survival rates of patients with stage II and III colorectal cancer

Zhao

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Molecular tumor markers hold considerable promise for accurately predicting the recurrence and progression of colorectal cancer (CRC) in patients. However, in the majority of cases, single marker analysis has been found to have low accuracy, and is of little practical use in clinical practice. The present study investigated the prognostic value of the combined detection of the protein expression of metastasis suppressor 23-H1 (Nm23-H1) and p53 using immunohistochemical analysis, and the mRNA expression levels were analyzed using reverse transcription-quantitative polymerase chain reaction in 110 cases of stage II and III CRC. The results revealed that the expression levels of Nm23-H1 in CRC tissues were lower, compared with those in normal tissues (χ2=18.249; P<0.001), and the protein expression levels of p53 were higher in the CRC tissues (χ2=23.940; P<0.001); although the mRNA expression levels of Nm23-H1 and p53 presented with the same trend. The protein expression of Nm23-H1 was correlated with lymph node metastases (χ2=11.847; P=0.001) and pathological patterns (χ2=6.911; P=0.032). However, it did not correlate with patient gender or age, or with tumor World Health Organization classification or invasive depth (P>0.05). No significant correlation was observed between the expression of p53 and clinicopathological features (P>0.05). Patients with CRC with Nm23-H1(+)/p53(−) tumors had increased survival rates, with a five-year overall survival rate of 83.8% and a five-year disease-free survival rate of 70.2%. The five-year overall survival rates in other study cohorts were lower, compared with the Nm23-H1(+)/p53(−) group (P<0.0125), and this was the same for the five-year disease-free survival rate (P<0.0125). In conclusion, the present study demonstrated that the combined detection of the protein expression of Nm23-H1 and p53 was associated with the long term survival rates of patients with stage II and III CRC; and this may offer potential for use as a predictor of survival rates in patients with CRC.

show abstract

“…Finally, 16 eligible studies were identified (Figure 1). [25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40] The main characteristics of the included studies, which were all retrospective, are summarized in Table 1 and Table 2. Among 16 studies, a total of 2030 UTUC patients ranging from 20 to 732 patients per study were reported.…”

Section: Study Selection and Characteristicmentioning

confidence: 99%

A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract urothelial carcinoma patients

Liao

et al. 2023

Tumori

View full text Add to dashboard Cite

Objective: The expression and significance of human epidermal growth factor receptor 2 (Her2) in upper tract urothelial carcinoma (UTUC) remains controversial. Thus, we aimed to systemically review the Her2 expression in UTUC patients and its relationship with pathological characters and clinical outcomes with meta-analysis. Materials and methods: A systematically computerized search in PubMed, Scopus, Embase and Cochrane was conducted. From a total of 454 related articles, 35 articles were finally reviewed and 16 papers were chosen for further analysis. Pathological characters included tumor stage, grade, lymph node metastasis (LNM) and lymphovascular invasion (LVI). The clinical outcomes included overall survival (OS), recurrence-free survival (RFS), cancer specific survival (CSS), metastatic-free survival (MFS) and progression-free survival (PFS). RevMan software was used for meta-analyses. Results: In total 16 studies from 1994 to 2020 were chosen, 14 studies used immunohistochemistry to assess the expression of Her2 and 5 studies used in situ hybridization, with a positive rate of 0 to 74.0% and 7.2 to 18.1%, respectively. Her2-positive was significantly associated with stage (pooled HR 1.86; 95 % CI 1.43–2.42), grade (pooled HR 2.81; 95 % CI 1.01–7.85) and LNM (pooled HR 1.93; 95 % CI 1.18–3.15). However, there was no statistically relationship between Her2-positive with LVI (pooled HR 1.48; 95 % CI 0.64–3.46) and RFS (pooled HR 1.41; 95 % CI 0.98–1.83). Conclusions: This review indicated that UTUC patients with Her2-positive tended to develop higher stage and grade tumors and LNM. The Her2 expression in UTUC patients deserves further investigation in the future.

show abstract

Expression of regulatory proteins and proliferative activity in relation to phenotypic characteristics of upper urothelial carcinoma

Abstract: This investigation showed that only negative regulatory proteins of the cell cycle, p53 and p16, were significantly associated in UUC, while proliferative marker Ki-67 was in relation to the key phenotypic characteristics of UUC in the best way.

Cited by 6 publications

References 34 publications

p53 Status Correlates with the Risk of Recurrence in Non-Muscle Invasive Bladder Cancers Treated with Bacillus Calmette–Guérin: A Meta-Analysis

p53 Status Correlates with the Risk of Recurrence in Non-Muscle Invasive Bladder Cancers Treated with Bacillus Calmette–Guérin: A Meta-Analysis

Combined detection of the expression of Nm23-H1 and p53 is correlated with survival rates of patients with stage II and III colorectal cancer

A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract urothelial carcinoma patients

Contact Info

Product

Resources

About